| Zelboraf (vemurafenib) / Roche |
NCT01001299: A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma |
|
|
| Completed | 1 | 25 | US | Drug cocktail, RO5185426 | Hoffmann-La Roche | Malignant Melanoma | 02/12 | 02/12 | | |
NCT01164891: A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma |
|
|
| Completed | 1 | 7 | Europe | RO5185426 | Hoffmann-La Roche | Malignant Melanoma | 12/12 | 12/12 | | |
NCT01107418: A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma |
|
|
| Completed | 1 | 52 | US, RoW | RO5185426 | Hoffmann-La Roche | Malignant Melanoma | 02/13 | 02/13 | | |
|
NCT01400451: Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) |
|
|
| Terminated | 1 | 18 | US | Ipilimumab (BMS-734016), Yervoy®, Ipilimumab, BMS-734016, Vemurafenib | Bristol-Myers Squibb, Roche-Genentech | Melanoma | 04/13 | 12/13 | | |
|
|
|
NCT01264380: A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma |
|
|
| Completed | 1 | 16 | US | RO5185426 | Hoffmann-La Roche | Malignant Melanoma | 05/13 | 05/13 | | |
NCT01765556: A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma |
|
|
| Withdrawn | 1 | 0 | US | ketoconazole, vemurafenib | Hoffmann-La Roche | Malignant Melanoma, Neoplasms | 10/13 | 10/13 | | |
NCT01611675: Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma |
|
|
| Terminated | 1 | 3 | US | Vemurafenib, Leflunomide | Massachusetts General Hospital | Melanoma | 01/14 | 01/14 | | |
NCT01849666: A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy |
|
|
| Completed | 1 | 2 | Europe | phenprocoumon, vemurafenib | Hoffmann-La Roche | Malignant Melanoma, Neoplasms | 04/14 | 04/14 | | |
NCT01765569: A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma |
|
|
| Completed | 1 | 29 | RoW | Digoxin, Vemurafenib | Hoffmann-La Roche | Malignant Melanoma, Neoplasms | 06/14 | 06/14 | | |
NCT01851824: A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy |
|
|
| Completed | 1 | 9 | Europe, RoW | acenocoumarol, vemurafenib, Zelboraf | Hoffmann-La Roche | Malignant Melanoma, Neoplasms | 06/14 | 06/14 | | |
NCT01844674: A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies |
|
|
| Completed | 1 | 18 | US, Canada, RoW | Tizanidine, Vemurafenib | Hoffmann-La Roche | Malignant Melanoma, Neoplasms | 08/14 | 08/14 | | |
NCT01835184: Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery |
|
|
| Terminated | 1 | 5 | US | cabozantinib-s-malate, BMS-907351, Cometriq, XL184, vemurafenib, BRAF(V600E) kinase inhibitor RO5185426, PLX4032, RG7204, RO5185426, laboratory biomarker analysis, pharmacological study, pharmacological studies | National Cancer Institute (NCI) | Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma, Unspecified Adult Solid Tumor, Protocol Specific | 09/14 | | | |
NCT02077114: Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma |
|
|
| Completed | 1 | 10 | Europe | Vaccine consisting of a peptide derived from the protein IDO, IDOlong | Herlev Hospital | Malignant Melanoma With Metastasis | 09/14 | | | |
NCT01841463: Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation |
|
|
| Suspended | 1 | 100 | US | P1446A-05, Vemurafenib (Zelboraf®) | Piramal Enterprises Limited, Melanoma Research Foundation Breakthrough Consortium | Advanced or Inoperable Malignant Melanoma With BRAF Mutation | 03/15 | 03/16 | | |
NCT00405587: Safety Study of PLX4032 in Patients With Solid Tumors |
|
|
| Completed | 1 | 109 | US, RoW | PLX4032 | Plexxikon, Roche Pharma AG | Malignant Melanoma, Colorectal Carcinoma | 07/15 | 02/16 | | |
|
NCT01765543: A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf) |
|
|
| Completed | 1 | 27 | US, RoW | Rifampin, Vemurafenib, RO5185426, Zelboraf | Hoffmann-La Roche | Malignant Melanoma, Neoplasms | 11/15 | 11/15 | | |
NCT02068079: A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma |
|
|
| Withdrawn | 1 | 0 | US | Vemurafenib and Trientine | Duke University | Melanoma | 11/15 | 11/15 | | |
| Terminated | 1 | 6 | US, Europe, RoW | vemurafenib, Zelboraf | Hoffmann-La Roche | Malignant Melanoma | 12/15 | 12/15 | | |
|
NCT02441465: Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies |
|
|
| Completed | 1 | 6 | Europe | Vemurafenib, Zelboraf®, RO5185426, 14C-Labeled Vemurafenib | Hoffmann-La Roche | Malignant Melanoma, Cancer | 08/16 | 01/17 | | |
NCT01943422: Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma |
|
|
| Completed | 1 | 7 | US | High-dose Interferon alfa-2b, IFNα-2b (HDI), Vemurafenib, Zelboraf | John Kirkwood, Merck Sharp & Dohme LLC | Melanoma | 11/16 | 12/16 | | |
NCT02145910: Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases |
|
|
| Withdrawn | 1 | 0 | US | Vemurafenib, Zelboraf, Whole-brain radiation therapy (WBRT), WBRT, whole brain radiotherapy, whole-brain radiotherapy, Radiosurgery (SRS), Radiation surgery, SRS | Sidney Kimmel Cancer Center at Thomas Jefferson University, Genentech, Inc. | Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain | 06/19 | | | |
| Withdrawn | 1 | 0 | US | Radiation therapy, Vemurafenib | University of Utah | BRAFV600 Mutation, Stage IV Melanoma | 08/22 | 08/22 | | |
